The 13 analysts offering 12-month price forecasts for Iovance Biotherapeutics Inc have a median target of 38.00, with a high estimate of 86.00 and a low estimate of 18.00. The median estimate represents a +49.25% increase from the last price of 25.46.
The current consensus among 14 polled investment analysts is to Buy stock in Iovance Biotherapeutics Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.53
Reporting Date Nov 04
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.